Citations

Clear

1053 citation(s) found for "Andre, F".

Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis
Wolf, Emily, Li, David, Fernandez, Andre, Gardner, Lindsay B., Rivera, Candido E., Wysokinska, Ewa , Shaikh, Marwan , Moustafa, Muhamad Alhaj , Wolf, Emily B , Fernandez, Andre J, Shaikh, Marwan E, Moustafa, Muhamad Alhaj , Tun, Han W. , Roy, Vivek

Mayo Clinic

Journal of Investigative Medicine High Impact Case Reports | November 3, 2023 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23247096231209543 | PMID 37919949 Get It

Factor VII (FVII) is an important, vitamin K-dependent clotting factor. Acquired FVII deficiency is a rare entity that is associated with serious bleeding complications. We report a case of acquired FVII deficiency in a patient with recurrent chronic myeloid leukemia in blast crisis who developed bilateral retinal hemorrhages. The coagulopathy was corrected with the initiation of chemotherapy and subsequent reduction in peripheral blast count.
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
Das, Saurav , Sher, Taimur , Fernandez, Andre, Parrondo, Ricardo , Parrondo, Ricardo D , Das, Saurav , Ailawadhi, Sikander , Roy, Vivek

Mayo Clinic

Current Oncology | October 31, 2023 | Volume: 30 | Issue: 11 | Pages: 9627-9633

10.3390/curroncol30110697 | PMID 37999117 Get It

While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis have been excluded from trials with these agents due to concerns of underlying autonomic, cardiac, and renal dysfunction, leading to potentially fatal toxicities from these therapies. In this communication, we described the outcomes of two patients with AL amyloidosis and concurrent MM with underlying cardiac and/or renal dysfunction who underwent anti-BCMA CAR T cell therapy with ide-cel or cilta-cel, received cytokine release syndrome prophylaxis, and tolerated therapy well with manageable toxicities and achieved a MRD-negative state. We described the preliminary efficacy and safety of CAR T in patients with AL amyloidosis and highlighted the importance of patient selection and medical optimization of cardiac and renal function prior to CAR T.
Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure
Bartúnek, Jozef , Terzic, André

Mayo Clinic

Texas Heart Institute Journal | October 26, 2023 | Volume: 50 | Issue: 5 | Pages: No page available

10.14503/thij-23-8247 | PMID 37881036 Get It

Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial
Yamada, Satsuki , Bartúnek, Jozef , Povsic, Thomas J. , Davison, Beth A. , Edwards, Christopher , Behfar, Atta , Metra, Marco , Filippatos, Gerasimos , Vanderheyden, Marc , Cotter, Gad , Davison, Beth A , Behfar, Atta , Metra, Marco , Filippatos, Gerasimos S , Vanderheyden, Marc , Wijns, William , Terzic, Andre , Bartunek, Jozef , Wijns, William , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | October 24, 2023 | Volume: 13 | Issue: 2 | Pages: 116-124

10.1093/stcltm/szad078 | PMID 38006196 Get It

Abstract Patients with heart failure experience limitations in daily activity and poor quality-of-life. Prospective surveillance of health-related quality-of-life supplemented traditional death and hospitalization outcomes in the multinational, randomized, double-blinded CHART-1 clinical trial that assessed cardiopoiesis-guided cell therapy in ischemic heart failure patients with reduced left ventricular ejection fraction. The Minnesota Living with Heart Failure Questionnaire (MLHFQ), a Food and Drug Administration qualified instrument for evaluating therapeutic effectiveness, was applied through the 1-year follow-up. Cell treated (n = 109) and sham procedure (n = 140) cohorts reported improved MLHFQ scores comparable between the 2 study arms (mean treatment difference with baseline adjustment −3.2 points, P = .107). Superiority of cell treatment over sham in betterment of the MLHFQ score was demonstrated in patients with pre-existing advanced left ventricular enlargement (baseline-adjusted mean treatment difference −6.4 points, P = .009). In this highly responsive subpopulation, benefit on the MLHFQ score paralleled reduction in death and hospitalization post-cell therapy (adjusted Mann-Whitney odds 1.43, 95% CI, 1.01-2.01; P = .039). The potential of cell therapy in addressing the quality-of-life dimension of heart failure requires further evaluation for disease relief.
Safety and Efficacy of Flow Diverters for Treatment of Unruptured Anterior Communicating Artery Aneurysms: Retrospective Multicenter Study
Benalia, Victor H. C. , Saatçi, Işıl , Cekirge, H Saruhan , Dabus, Guilherme , Brinjikji, Waleed , Nishi, Hidehisa , Siddiqui, Adnan H. , Aghaebrahim, Amin, Sauvageau, Eric , Saatci, Isil , Çekirge, Saruhan , Dabus, Guilherme C. , Nishi, Hidehisa , Monteiro, Andre , Aghaebrahim, Amin , Hanel, Ricardo A , Siddiqui, Adnan H , Cortez, Gustavo M , Mounayer, Charbel , Koçer, Naci , Işlak, Civan , Baltacıoğlu, Feyyaz , Mendes Pereira, Vitor , Lopes, Demetrius K. , Hanel, Ricardó A.

Mayo Clinic

Journal of NeuroInterventional Surgery | October 16, 2023 | Volume: 15 | Issue: 12 | Pages: 1181-1186

10.1136/jnis-2023-020673 | PMID 37845019 Get It

Background The anterior communicating artery (AComm) region is the most common site of intracranial aneurysms, with increased rupture risk compared with other locations. Overall, flow diverters present as a safe and efficacious treatment for intracranial aneurysms, but there is paucity of data for their use in the treatment of unruptured AComm aneurysms. We present the largest multicentric analysis evaluating the outcomes of flow diverters in AComm aneurysm treatment. Methods Databases from 10 centers were retrospectively reviewed for unruptured AComm aneurysms treated with flow diverters. Demographics, clinical presentation, radiographic characteristics, procedural complications, and outcomes were assessed. Results A total of 144 patients harboring 147 AComm aneurysms were treated between January 2012 and December 2021. Seventy-four were women (51.4%) and median age was 60 (IQR 50–67) years. All were unruptured AComm aneurysms. Half of the cohort had similar anterior cerebral artery sizes (51.4%). The most common morphology was saccular (94.6%), with a branch involvement in 32.7% of cases. Median vessel diameter was 2.4 mm, and the Pipeline Flex was the most prevalent device (32.7%). Median follow-up time was 17 months, with complete occlusion in 86.4% at the last follow-up. Functional independence (modified Rankin Scale score 0–2) was reported in 95.1%. Intraprocedural complications occurred in 5.6%, and postoperative complications were noted in 9.7% of cases. Combined major complication and mortality rate was 2.1%. Conclusions Our study suggests that flow diverters are a useful treatment for AComm aneurysms. Mid-term results indicated favorable aneurysm occlusion with a good safety profile. Additional prospective studies with longer follow-up periods and independent adjudication are warranted to better assess these results.
Executive Summary: Guidelines for Evaluating New Fever in Adult Patients in the ICU
O’Grady, Naomi P., Alexander, Earnest, Alhazzani, Waleed , Alshamsi, Fayez , Cuellar‐Rodríguez, Jennifer , Jefferson, Brian , Patel, Robin , Deresinski, Stanley C. , Patel, Robin , Kalil, André C. , Pastores, Stephen M. , van Duin, David , Weber, David J.

Mayo Clinic

Critical Care Medicine | October 12, 2023 | Volume: 51 | Issue: 11 | Pages: 1566-1569

10.1097/ccm.0000000000006021 | PMID 37902339 Get It

Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU
O’Grady, Naomi P., Alexander, Earnest, Alhazzani, Waleed , Alshamsi, Fayez , Cuellar‐Rodríguez, Jennifer , Jefferson, Brian , Patel, Robin , Deresinski, Stanley C. , Patel, Robin , Kalil, André C. , Pastores, Stephen M. , van Duin, David , Weber, David J.

Mayo Clinic

Critical Care Medicine | October 12, 2023 | Volume: 51 | Issue: 11 | Pages: 1570-1586

10.1097/ccm.0000000000006022 | PMID 37902340 Get It

RATIONALE: Fever is frequently an early indicator of infection and often requires rigorous diagnostic evaluation. OBJECTIVES: This is an update of the 2008 Infectious Diseases Society of America and Society (IDSA) and Society of Critical Care Medicine (SCCM) guideline for the evaluation of new-onset fever in adult ICU patients without severe immunocompromise, now using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. PANEL DESIGN: The SCCM and IDSA convened a taskforce to update the 2008 version of the guideline for the evaluation of new fever in critically ill adult patients, which included expert clinicians as well as methodologists from the Guidelines in Intensive Care, Development and Evaluation Group. The guidelines committee consisted of 12 experts in critical care, infectious diseases, clinical microbiology, organ transplantation, public health, clinical research, and health policy and administration. All task force members followed all conflict-of-interest procedures as documented in the American College of Critical Care Medicine/SCCM Standard Operating Procedures Manual and the IDSA. There was no industry input or funding to produce this guideline. METHODS: We conducted a systematic review for each population, intervention, comparison, and outcomes question to identify the best available evidence, statistically summarized the evidence, and then assessed the quality of evidence using the GRADE approach. We used the evidence-to-decision framework to formulate recommendations as strong or weak or as best-practice statements. RESULTS: The panel issued 12 recommendations and 9 best practice statements. The panel recommended using central temperature monitoring methods, including thermistors for pulmonary artery catheters, bladder catheters, or esophageal balloon thermistors when these devices are in place or accurate temperature measurements are critical for diagnosis and management. For patients without these devices in place, oral or rectal temperatures over other temperature measurement methods that are less reliable such as axillary or tympanic membrane temperatures, noninvasive temporal artery thermometers, or chemical dot thermometers were recommended. Imaging studies including ultrasonography were recommended in addition to microbiological evaluation using rapid diagnostic testing strategies. Biomarkers were recommended to assist in guiding the discontinuation of antimicrobial therapy. All recommendations issued were weak based on the quality of data. CONCLUSIONS: The guidelines panel was able to formulate several recommendations for the evaluation of new fever in a critically ill adult patient, acknowledging that most recommendations were based on weak evidence. This highlights the need for the rapid advancement of research in all aspects of this issue—including better noninvasive methods to measure core body temperature, the use of diagnostic imaging, advances in microbiology including molecular testing, and the use of biomarkers.
OP056 A systematic review on the use of local infiltration of liposomal bupivacaine in breast surgery
Vilela, Ramon Mendonça, Dias, Andrei Sanson, Kreutz‐Rodrigues, Lucas , Dias, Andrei , Brandão, Gabriela Rangel , Schmidt, André P. , Amaral, Sara

Mayo Clinic

Postoperative pain management – Free papers 7 | October 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: A34.2-A35

10.1136/rapm-2023-esra.56 Get It

FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
Fansa, Sima , Tama, Elif , Nicolalde, Bryan , D’Andre, Stacy D. , Ghusn, Wissam , Añazco, Diego , Faubion, Stephanie S. , Shufelt, Chrisandra , Acosta, Andrés , Hurtado, Maria D.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.087 Get It

Abstract Disclosure: S. Fansa: None. W. Ghusn: None. E. Tama: None. B. Nicolalde: None. D. Anazco: None. S. D'Andre: None. S. Faubion: None. C. Shufelt: None. A. Acosta: None. M.D. Hurtado: None. Background: Aromatase inhibitors (AIs) block estrogen synthesis and are used as adjuvant treatment for breast cancer. AIs are associated with weight gain that can lead to increased cardiometabolic risk, thereby affecting health and survivorship quality in these patients. The role of anti-obesity medications (AOMs) in patients using AIs has not been studied. We sought to investigate weight loss outcomes to AOMs in patients taking AIs for breast cancer treatment. Methods: This is a matched case-control retrospective cohort study of breast cancer survivors on AI using FDA-approved AOMs (AI/AOM group). We compared their weight loss outcomes with a group of female patients with obesity, without a history of breast cancer or AI use, on AOMs (AOM group). We matched patients by age and body mass index (BMI). Exclusion criteria: AOM initiation prior to AI therapy, ≤3 months of AOM use, history of bariatric surgery, active malignancy, or pregnancy. Primary endpoint: total body weight loss % (TBWL%) at 12 months. Secondary endpoints: TBWL% at 3 and 6 months and % of patients achieving categorical TBWL ≥5%, ≥10% and ≥15% at 12 months. We used Pearson χ2 and unpaired t-test to compare baseline characteristics and outcomes between groups, and univariate analyses to estimate the contribution of variables to TBWL% in the AI/AOM group. We present results as mean ± standard deviation. Results: We included 99 patients: 63 in the AI/AOM group (63.5±10 years, BMI 34.4±7.0 kg/m2) and 36 in the AOM group (60.4±8.7 years, BMI 36.3±6.9 kg/m2). Liraglutide, semaglutide and phentermine were the only AOMs used. There was no difference in the frequency of use of these three AOMs among both groups (p= 0.1). AI/AOM group had a lower TBWL% compared to the AOM group during follow-up: 3.7± 4.3% vs. 5.6 ± 4.1% (p= 0.03) at 3 months, 3.9± 4.3% vs. 9.5± 4.7% (p< 0.0001) at 6 months, and 5.2± 5.3% vs. 10.5± 6.8% (p< 0.0001) at 12 months. Although the AI/AOM group was more likely to use lower doses of AOMs (p= 0.0004), TBWL% differences persisted among groups at 12 months after adjusting for AOM dosing (p< 0.0001). There was no difference in nutritional and behavioral modification sessions among groups (p=0.06 and p=0.9, respectively). At 12 months, the percentage of patients achieving ≥5%, ≥10%, and ≥15% TBWL was greater in the AOM group compared to the AI/AOM group: ≥5% TBWL, 85.7% vs. 50.0% (p< 0.0001); ≥10%, 57.1 vs. 20.0% (p< 0.0001); and ≥15%, 28.6 vs. 5.0% (p< 0.0001); respectively. We found no predictors of TBWL% at 12 months in the AI/AOM group. Conclusion: Weight loss outcomes in breast cancer survivors on AIs taking AOMs are poorer compared to patients without breast cancer history and not taking AIs. Studies are needed to assess the mechanisms behind the different weight loss response to AOMs in women taking AIs, which we hypothesize may relate to AIs’ anti-estrogenic effect on lean and fat mass. Presentation: Friday, June 16, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho, Teresa , Dasgupta, Noel R., Parman, Yeşim , França, Marcondes C. , Guo, Yuh‐Cherng , Wixner, Jonas , Ro, Long‐Sun , Calandra, Cristian , Kowacs, Pedro André , Weiler, Markus , Jung, Shiangtung W., Büchele, Gustavo, Chen, Jersey , Hughes, Steven G. , Schneider, Eugene, Viney, Nicholas J. , Masri, Ahmad , Gertz, Morie R., Ando, Yukio, Khella, Sami, Dyck, P. James B. , Investigators, NEURO-TTRansform, Gane, Edward , Dávila, Lucía Galán, Mezei, Michelle M. , Moreno, Juan González, Cintas, Pascal , Traub, Rebecca , Khoury, Julie, Estol, Conrado J. , Polydefkis, Michael , Brannagan, Thomas H., Rugiero, Marcelo, Distad, B. Jane, Papanicolaou, Eleni Zamba, Lin, Kon‐Ping, Benson, Merrill D., Scheinberg, Morton , Gillmore, Julian D , Marques, Wilson , Chao, Chi‐Chao , Berk, John L. , Obici, Laura , Barroso, Fábio , Conceição, Isabel , Brambatti, Michela , Gertz, Morie A. , Ando, Yukio, Gillmore, Julian D. , Waddington‐Cruz, Márcia , Investigators, NEURO-TTRansform, Mazzeo, Anna Teresa , Papagianni, Aikaterini E. , Dimachkie, Mazen M. , Zaganas, Ioannis V. , Luigetti, Marco , Pareyson, Davide , Needham, Merrilee , Adams, David , Bril, Vera , Attarian, Shahram , Lin, Kon‐Ping

Mayo Clinic

JAMA | September 28, 2023 | Volume: 330 | Issue: 15 | Pages: 1448

10.1001/jama.2023.18688 | PMID 37768671 Get It

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P < .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10